Scope Fluidics Group, active in the life science sector and listed on the Warsaw Stock Exchange, develops innovative technologies for the medical diagnostics and healthcare markets. At the end of the second quarter of 2025, the Group held approximately PLN 123 million in cash.
The Group is currently developing three special-purpose companies: BACTEROMIC, as well as two new firms spun out of Scope Discovery – EDOCERA, which has already completed the technology validation process and has begun work on a device prototype, and HYBOLIC. The Group plans to step up investments in these ongoing projects.
“We are consistently advancing our key projects. Our priority is BACTEROMIC, our next candidate – after PCR|ONE – for a partnership with a global distributor. Early Access results confirm the system’s market readiness. In parallel, we are conducting IVDR certification and launching a semi-automated panel production line in cooperation with a global leader. We have also signed an agreement with a U.S. FDA advisor to conduct clinical trials for FDA certification of the Bacteromic system with the FAST UNI panel. We are also strengthening our other companies. Following technology validation, EDOCERA has started developing a prototype device for stroke prevention and diagnostics. EDOCERA is a breakthrough solution with major significance for public health. In the near term, we will continue to strengthen our market position and advance innovative projects,” says Piotr Garstecki, President of Scope Fluidics.
It should also be noted that in the first quarter of this year, the Group achieved the first of its strategic objectives under the Scope Fluidics Development Strategy ahead of schedule. The goal was that by the end of 2025, the Group would have at least five new projects in its portfolio, including at least two in the form of special-purpose companies.
The role of hub for creating and developing new projects within the Group is played by Scope Discovery – an internal Venture Studio–type organization responsible for generating and advancing projects in a repeatable, structured model. By the end of the first half of the year, 63 projects had been registered for review under the Scope Discovery process. Of these, 17 had been closed, 26 were in progress, and another 18 were awaiting evaluation.
Time for investment
At the end of the second quarter of 2025, the Group held more than PLN 123 million in cash – approximately PLN 100 million in cash and bank deposits, and around PLN 23 million in investment fund units.
“We are currently allocating a significant share of our investment resources to developing the BACTEROMIC system, preparing the company for a potential M&A transaction. Investing in advanced technologies is a long-term process requiring not only specialized expertise and strong professional support, but also a prudent and flexible approach to financial management. Maintaining a strong cash position and diversifying funding sources remain key priorities, strengthening our negotiating power and maximizing the Group’s value. At the same time, we are aware of the major investments ahead that will shape the organization’s future in the coming years. For this reason, we have opened the way to an increase in authorized capital and are analyzing other available financing options – including the possibility of obtaining up to EUR 15 million in funding from the European Investment Bank. The fact that our projects are winning the trust of European institutions confirms our chosen strategy and represents an important element of funding diversification, giving us greater flexibility and operational security,” emphasizes Szymon Ruta, Vice President and Chief Financial Officer of Scope Fluidics.
After the reporting period, Scope Fluidics received a financing proposal from the EIB (Term Sheet). The potential financing would be provided in three tranches: Tranche A – up to EUR 4 million, Tranche B – up to EUR 5 million, and Tranche C – up to EUR 6 million. Each tranche carries an 8% interest rate (payable upon repayment of the tranche) and 1% interest payable semi-annually or annually. Repayment of each tranche will be made in a single payment after six years. In addition, the EIB will receive warrants. Activation of Tranche A, Tranche B, and Tranche C will grant rights to exercise warrants corresponding to 1.95%, 1.65%, and 1.35% of Scope Fluidics shares, respectively.
Scope Fluidics has previously drawn on EIB financing. In September 2020, the company signed a financing agreement with the European Investment Bank for EUR 10 million, under which it drew two tranches totaling EUR 7 million. Access to EIB financing was an important factor that positively influenced the process and terms of the sale of the special-purpose company Curiosity Diagnostics to Bio-Rad Laboratories for USD 130 million – the largest transaction in the history of the Polish life science market.
